[{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merakris Therapeutics \/ University of Texas Medical Branch","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ University of Texas Medical Branch"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"US Department of Veterans Affairs","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Human Amniotic Fluid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merakris Therapeutics \/ US Department of Veterans Affairs","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ US Department of Veterans Affairs"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"IND Enabling","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Merakris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Merakris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merakris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merakris Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merakris Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Human Amniotic Fluid","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Merakris Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Merakris Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Merakris Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Merakris Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Dermacyte (human amniotic fluid), a cell-free amniotic injection, that is being developed in Phase 2 clinical trial for the treatment of venous stasis ulcer.

                          Brand Name : Dermacyte

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 05, 2024

                          Lead Product(s) : Human Amniotic Fluid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Dermacyte (human amniotic fluid), a cell-free amniotic injection, that is being developed in Phase 2 clinical trial for the treatment of venous stasis ulcer.

                          Brand Name : Dermacyte

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 05, 2023

                          Lead Product(s) : Human Amniotic Fluid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Dermacyte® Amniotic Wound Care Liquid (human amniotic fluid), a cell-free amniotic injection that is being developed under Merakris’ investigational New Drug (IND) approval for would healing.

                          Brand Name : Dermacyte Liquid

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          November 29, 2022

                          Lead Product(s) : Human Amniotic Fluid

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Merakris has entered into a Cooperative Research and Development Agreement with the VA and is currently negotiating with additional clinical sites to conduct the two-part Phase II clinical trial for Dermacyte, Human Amniotic Fluid.

                          Brand Name : Dermacyte

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 27, 2022

                          Lead Product(s) : Human Amniotic Fluid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : US Department of Veterans Affairs

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : A single combination treatment with Dermacyte Liquid and Dermacyte Matrix (Human Amniotic Fluid) healed smaller of two wounds in four weeks. Dermacyte Liquid was injected under skin around wounds on patient’s thigh and lower leg.

                          Brand Name : Dermacyte Liquid

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 02, 2022

                          Lead Product(s) : Human Amniotic Fluid

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : The University of Texas MD Anderson Cancer Center

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank